Skip to content

A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02406872
Enrollment
144
Registered
2015-04-02
Start date
2014-12-31
Completion date
2015-08-31
Last updated
2015-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Brief summary

The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as an intravenous general anaesthetic drug in operations and to determine its efficacy and safety profile comparing to propofol.

Detailed description

This is an multi-center,double-blinded,parallel and control study using Remimazolam or propofol for anesthesia in operations.Subjects are randomized to different treatment groups (including 3 for Remimazolam Tosilate and 1 for propofol) and anaesthetics are pumped contimuously into bodies.Analgesics and muscle relaxants are permitted during operations.Efficacy,safety and pharmacokinetic/pharmacodynamic profiles of Remimazolam Tosilate are to be evaluated.

Interventions

IV pumping for anesthesia

DRUGPropofol

IV bolus for anesthesia

Sponsors

Jiangsu HengRui Medicine Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* subjects aged 18-60 years; * intending to have non-emergency operations; * ASA( American Society of Anesthesiologists) I or II; * 18 kg/m²\<BMI(Body Mass Index)\<30 kg/m².

Exclusion criteria

* people with contraindications to general anaesthesia; * one or more of the laboratory findings fall out of the limitations for this study(platelet,hemoglobin,aspartate aminotransferase,etc.); * history of recent use of narcotics,analgesics,anaesthetics and benzodiazepine hypnotics; * history of severe cardiovascular disease; * uncontrolled blood glucose level; * cerebral disease or mental disorder; * allergic to drugs used in the study; * pregnant women or those in lactation period.

Design outcomes

Primary

MeasureTime frame
successful anaesthesia rate as measured by the proportion of subjects who experienced succesful anesthesia during operationsan average of 3 hours (immediately after opaerations)

Secondary

MeasureTime frame
bispectral index(BIS) during anaesthesia as measured by bispectral index machineevery 5 minutes
recovery time as measured by timean average of 3 hours (after cessation of anesthetics pumping)
induction time as measured by time1-10 minutes (from the begining of anesthetics)

Other

MeasureTime frame
rate of hypotention as measured by the proportion of subjects who experienced hypotention during operationsan average of 3 hours (after anesthesia)
rate of hyoxemia as measured by the proportion of subjects who experienced hyoxemia during operationsan average of 3 hours (after anesthesia)
rate of improper-depths sedation as measured by the proportion of subjects who experienced too-deep or too-shallow anesthesia during operationsan average of 3 hours (after anesthesia)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026